Zevra Therapeutics(NASDAQ) ZVRA

Zevra helps people with rare diseases get the treatments they need. It makes and sells drugs for brain and metabolic conditions. These therapies help patients manage symptoms when other options are limited.

Medicines for Rare Conditions

• MIPLYFFA: Oral medicine for the neurological symptoms of Niemann-Pick disease type C (NPC), a rare and progressive brain disorder.
• OLPRUVA: Flavored oral suspension for ammonia control in urea cycle disorders (UCDs), which are rare genetic conditions.
• AZSTARYS: Once-daily treatment for attention deficit hyperactivity disorder (ADHD); managed by a partner and provides royalty and milestone income.
• Celiprolol: Investigational drug in late-stage testing for Vascular Ehlers-Danlos syndrome (VEDS), a condition that causes fragile blood vessels and organs.
• KP1077: Candidate for sleep disorders like idiopathic hypersomnia, which is characterized by excessive daytime sleepiness and extreme difficulty waking.

Growing Through Strategic Deals

• Purchased the assets of Orphazyme A/S in May 2022 to acquire arimoclomol, which the FDA later approved as MIPLYFFA.
• Acquired Acer Therapeutics, Inc. in November 2023 to add the drug OLPRUVA and clinical-stage candidate celiprolol to its pipeline.
• Licensed the worldwide commercialization rights for the ADHD treatment AZSTARYS to Commave under a partnership agreement.
• Finalized the sale of a priority review voucher in April 2025, which generated $148.3 million in net proceeds.

Better Medicine Through Chemistry

Zevra uses its Ligand Activated Therapy (LAT) technology to create prodrugs. These are inactive substances that convert into active medicine inside the body to improve drug safety or effectiveness.

A Shift Toward Profitability

• Revenue was $34.1 million in Q4 2025, up 183.4% from $12 million in Q4 2024.
• Net income reached $12.2 million in Q4 2025, an improvement from a loss of $35.7 million in Q4 2024.
• Operating income turned positive at $9.3 million in Q4 2025 compared to a $15.4 million loss in Q4 2024.
• Free cash flow hit $5.5 million in Q4 2025, improved from a $16.2 million loss in Q4 2024.

Bottom Line

Zevra has evolved from a research-focused firm into a commercial rare-disease company with multiple approved products. Its expansion through strategic acquisitions and proprietary prodrug technology supports its goal of treating high-need medical conditions.